The short version of NR1D1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Similarly, Sumo wrestlers are typically categorized by BMI as "severely obese" or "very severely obese", but one study of college-aged Sumo wrestlers found that 40% of them were no longer categorized as obese when body fat percentage (with a cutoff of <25%) was used instead of BMI; this was attributed to their very high lean body mass. The Edmonton Obesity Staging System (EOSS), developed in Canada, supplements BMI-based classification by incorporating medical, functional, and mental-health factors into a five-stage clinical framework.
=== Occurrence in cereals === The alkylresorcinols alkyl chain, present in cereals, ranges from 15 to 25 carbon atoms. ARs have been reported to be present in high amounts in rye, wheat, and triticale, and in low concentrations in barley, maize, oat, and millet, while no information is at present available for Khorasan wheat. They are most abundant in the bran fractions (2600-4100 μg/g; 0.1-0.3% of dry weight), whereas they are in trace amounts in strachy endosperm and germ. They can also be found in rice, though not in the edible parts of the rice plant. Their presence in the endosperm (the part of cereal grain that is used to make white flour), means that alkylresorcinols can be used as 'biomarkers' for people who eat foods containing wholegrain wheat and rye, rather than cereal products based on white flour. Moreover, they were thought to have anti-nutritive properties (e.g. decreasing growth of pigs and chickens fed rye), but this theory has been discredited, and a number of animal studies have demonstrated that they have no obvious negative effect on animals or humans, while recent studies suggest they may have some health benefits as activators of the enzyme SIRT3, with the 17-carbon homologue 5-heptadecylresorcinol showing strongest activity.
== Anatomy == The pulp is the neurovascular bundle central to each tooth, permanent or primary. It is composed of a central pulp chamber, pulp horns, and radicular canals. The large mass of the pulp is contained within the pulp chamber, which is contained in and mimics the overall shape of the crown of the tooth. Because of the continuous deposition of the dentine, the pulp chamber becomes smaller with the age. This is not uniform throughout the coronal pulp but progresses faster on the floor than on the roof or sidewalls. Radicular pulp canals extend down from the cervical region of the crown to the root apex. They are not always straight but vary in shape, size, and number. They are continuous with the periapical tissues through the apical foramen or foramina. The total volume of all the permanent teeth organs is 0.38cc, and the mean volume of a single adult human pulp is 0.02cc. Accessory canals are pathways from the radicular pulp. These canals, which extend laterally through the dentin to the periodontal tissue, are seen especially in the apical third of the root. Accessory canals are also called lateral canals because they are usually located on the lateral surface of the roots of the teeth.
=== Tax avoidance === In June 2021, the United States Senate Finance Committee, under Chair Ron Wyden (D-OR), began an investigation to determine if the company took advantage of loopholes in the Tax Cuts and Jobs Act of 2017 to significantly reduce its tax liability. In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. The report, released in July 2022, showed that AbbVie was able to dodge U.S. taxes by registering intellectual property in offshore jurisdictions such as Bermuda. As a result, while AbbVie received 75% of its sales of Humira in the United States, it only reported 1% of that income for U.S. tax purposes.
Sources: en.wikipedia.org
==== Evolutionary covariation to predict 3D contacts ==== As sequencing became more commonplace in the 1990s several groups used protein sequence alignments to predict correlated mutations and it was hoped that these coevolved residues could be used to predict tertiary structure (using the analogy to distance constraints from experimental procedures such as NMR). The assumption is when single residue mutations are slightly deleterious, compensatory mutations may occur to restabilize residue-residue interactions. This early work used what are known as local methods to calculate correlated mutations from protein sequences, but suffered from indirect false correlations which result from treating each pair of residues as independent of all other pairs. In 2011, a different, and this time global statistical approach, demonstrated that predicted coevolved residues were sufficient to predict the 3D fold of a protein, providing there are enough sequences available (>1,000 homologous sequences are needed). The method, EVfold, uses no homology modeling, threading or 3D structure fragments and can be run on a standard personal computer even for proteins with hundreds of residues. The accuracy of the contacts predicted using this and related approaches has now been demonstrated on many known structures and contact maps, including the prediction of experimentally unsolved transmembrane proteins.
The park was closed for renovations on July 11, 1988. The four-year project to rebuild Bryant Park entailed new entrances, repairs to paths and lighting, and a redesign of the park's garden by Lynden Miller. Biederman worked with William H. Whyte, a sociologist whose influence led them to implement two decisions. One was the placement of 2,000 movable chairs in the park. The other was to lower the park itself, because Bryant Park had been elevated from the street and isolated by tall hedges prior to the 1988 redesign. The 1988 renovation lowered the park to nearly street level and tore out the hedges, though much of the park was still slightly elevated. The park's restrooms, which had been closed for 35 years, were renovated as well. The BPRC also found that several of the sculptures would need to be repaired, and called on William Cullen Bryant's descendants and other entities to provide funding for the restoration of these sculptures. Landscape architect Laurie Olin of Hanna/Olin recalls that the design process focused on "the different abilities of people [who] use these spaces...as well as making spaces that people are comfortable being with each other in." The restoration cost $8.9 million, which included $5.7 million of city funding and $3.2 million of private funding. The renovation took place at the same time as the NYPL's expansion of the main branch's stacks underneath Bryant Park.
== Equations == The Beer–Lambert law states that there is a logarithmic dependence between the transmission (or transmissivity), T, of light through a substance and the product of the absorption coefficient of the substance, α, and the distance the light travels through the material (i.e. the path length), ℓ. The absorption coefficient can, in turn, be written as a product of either a molar absorptivity of the absorber, ε, and the concentration c of absorbing species in the material, or an absorption cross section, σ, and the (number) density N of absorbers. (see Beer Lambert Law link for full derivation)
The beta blocker pindolol has been found to robustly potentiate the effects of DMT. This is thought to be due to pindolol's serotonin 5-HT1A receptor antagonism, which is thought to disinhibit the effects of DMT. The serotonin receptor agonist methysergide (UML-491) has been reported to greatly intensify the effects of DMT.
Narrated by Paul Brightwell, produced by David Sington, directed by David McNab, made by Dox Productions 4 March The Engines That Came in from the Cold, about the Russian N1 rocket with an unexpected and surprising outcome to the documentary, and a reference to the 1963 book The Spy Who Came in from the Cold; George Mueller, head of Apollo programme from 1963 to 1969; Charles Vick of the Federation of American Scientists; Sergei Korolev, chief designer at OKB-1; Vasily Mishin, deputy chief designer at OKB-1, had done calculations showing that to get a cosmonaut on the Moon, it required a 100 tonne vehicle in orbit, which would require a 2,000 tonne vehicle at lift-off; Valentin Anisimov, chief designer at Kuznetsov Design Bureau, and how Korolev approached the Kuznetsov company, to make the new rocket engines for the proposed N1 rocket launcher, but it was too new and large to develop from scratch, so thirty pre-existing engines would be deployed, and the pre-burner which powered the rocket pumps would become a closed cycle, to improve power by 25%, but this was vastly untested; the first twelve launches would be uncrewed, followed by two test crewed launches, and the Soviet limited budget meant that development was not at a sufficient stage (that NASA would have arrived at) before the launches were carried out; this first uncrewed launch took place on 21 February 1969, and one minute into the flight, the rocket exploded; the N1 had a thrust of 4,500 tonnes at launch; the N1 second launch took place on 3 July 1969, after the engine control system was modified, and a few seconds after launch the engine cut out, and the whole N1 launcher fell onto the launch pad, causing total catastrophic results - this explosion stopped any further Soviet Union attempt to reach the Moon with a crewed rocket, the launch pad damage was unrecoverable; two weeks later Apollo 11 landed on the Moon; the N1 next launch was on 26 June 1971, with a rebuilt launch pad, and this launch exploded one minute into the flight; the fourth launch of the N1 on 23 November 1972 exploded two minutes into the flight; by the mid-1970s the Kuznetsov NK-33 closed-cycle engine, for the N1, had been sufficiently tested in its development lifetime; the Soviet Moon mission was around four years behind NASA, and when the engines were finally sufficiently tested, the whole Soviet Moon programme was stopped in 1974; any N1 engines and systems were instructed to be removed, to eliminate its knowledge; only in the early 1990s did knowledge of the N1 first appear; Bob Ford of Lockheed Martin and Bill Hoffman of Aerojet; Kuznetsov had nonetheless kept around sixty NK-33 engines in Samara - the home of Soviet rocketry, and wanted to show these engines to visitors from Aerojet; after a successful test of an NK-33 at Sacramento in October 1995, the NK-33 was developed into the RD-180, which powered the American Lockheed Martin Atlas III rocket; John Karas, of Lockheed Martin, at the first launch of an American rocket, on 24 May 2000 of the Eutelsat 36A satellite, that was powered by a Russian engine - the RD-180, which was twice as powerful as the NK-33, and one engine could replace five engines of the previous Atlas II; Vladimir Chvanov and Boris Katorgin, designers at NPO Energomash; the American rocket engineers had viewed the closed-cycle method as far too dangerous, and it was dangerous, but Russian engineers had developed new stainless steel alloys to largely overcome this danger. Narrated by Jaye Griffiths, produced by Hamish Barbour, directed by, made by Ideal World Productions 17 June The Day the Oceans Boiled, about the Earth's environment; 55 million years ago, the Earth was 6C hotter than it is now, with no ice caps, and trees grew at Antarctica, the temperature became 8C hotter, known as the Paleocene-Eocene Thermal Maximum; mammals shrunk in how large; since 55m years ago, carbon dioxide has been absorbed by plants, cooling the Earth; climate models were derived from weather forecast models; Peter Cox (climatologist) of the Met Office, and carbon sinks, and how each year 6 billion tonnes of carbon dioxide enters the atmosphere, but the effect appears to be only from around 3 billion tonnes; Antonio Nobre of the National Institute of Amazonian Research - he found that the Amazon forest, and its 500 million hectares of trees, was a much bigger carbon sink than presumed - it could be absorbing three-quarters of the carbon dioxide of all the world's vehicles; the Greenland Ice Sheet Project, and Geoffrey Hargreaves at the National Science Foundation Ice Core Facility (NICL) in Colorado, and ice cores from the Vostok Station; the Earth has warmed and cooled in a 100,000 years cycle; the Met Office model predicted that after 2050, due to shortage of rainfall seasons, the Amazon forest would not act as a carbon sink; Carlos Nobre (scientist) and dry seasons, and the possible danger of fire, caused by changes in the tropical climate; Richard Corfield (scientist); Philip D. Gingerich of the University of Michigan; Santo Bains was researching the Paleocene-Eocene boundary, so went to the Gulf Coast Repository, and looked at Core 690 drilled by JOIDES Resolution of the Ocean Drilling Program from the Weddell Sea, and concluded that rapid changes in Earth temperature came from methane clathrates (methane hydrates); geologist Euan Nisbet; the Earth returned to lower temperatures after 60,000 years. Narrated by Matthew Zajac, directed by David Sington, made by Dox Productions 24 June The Fish That Time Forgot, about the coelacanth; Margery Courtney Latimer in 1938 of the Natural History Museum, London, and a fish caught at East London; J. L. B. Smith, from Grahamstown, of Rhodes University; the American Museum of Natural History; evolutionary biologist John McCusker; the Comoro Islands, run by the French, near Madagascar, where another fish was found in 1952; Mike Ruton; Robin Stobbs; the JAGO (German research submersible) and Hans Fricke of the Max Planck Institute for Behavioral Physiology, who found a live fish on 17 January 1987; Susan Jewett of the National Museum of Natural History in Washington; on 30 July 1998, a live female fish is found on a beach in Indonesia by Mark Erdmann. Narrated by Robert Lindsay, produced by Ron Ackerman, directed by Celia Lowenstein, made by Diverse Productions with Nova 8 July The Secret Life of the Mouse, about the laboratory mouse; zoologist Sam Berry of UCL; mouse geneticist Jo Peters of MRC Harwell; Irving Weissman; most genetic research is done with mice, with 25 million a year; Steve Brown, Director of MRC Harwell; the mouse has 99.9% of the genes of humans; the Jackson Laboratory has 1m mice and around 1,000 human staff, with 2,500 strains of mice, who have mouse models of human diseases, and mice breed much quicker than humans do; Beverly Paigen; in one year, there are three generations of mice; twenty Nobel prizes have depended on mouse research; Cliffe Rosen of the Maine Center of Osteoporosis Research; scientists want mutant mice for each gene; Charles Vacanti of the University of Massachusetts Medical School, whose cartilage research led to a mouse having an artificial cartilage human ear grown on its back; Philip Leder of Harvard Medical School, who placed a patent on a mouse; a fluorescent mouse; Hank Greely of Stanford University; it ends with the opening lines from A Tale of Two Cities. Narrated by Stephen Fry, produced by David Paterson, directed by Kevin Hull, made by BOA 2001. The documentary has overtones of the music video of the 2001 Where's Your Head At, made in the same year as the documentary 15 July Saving the Leaning Tower, a documentary chronicling the dramatic rescue of one of the world’s most iconic landmarks. By the late 1980s, the Leaning Tower of Pisa was on the brink of collapse, its southward tilt increasing steadily and threatening catastrophic failure. Alarm spread after the sudden fall of a medieval bell tower in Pavia in 1989, which convinced authorities to close Pisa’s monument to the public. An international committee of engineers, geologists, and historians was formed to save the tower, among them British civil engineer John Burland. Through detailed investigation, the team uncovered the structural weaknesses behind the marble façade and the unstable soils beneath Pisa. Computer models showed the tower should already have collapsed. Temporary steel tendons and 600 tonnes of lead counterweights prevented immediate disaster, but the tower’s fate remained uncertain. Burland proposed a novel, delicate solution: controlled “soil extraction” below the northern side to allow the tower to gently tilt back to stability. The project was plagued by risks, political disputes, and near-disasters, including the “Black September” of 1995, when freezing the foundations caused the tower to lurch alarmingly. Despite opposition, the soil extraction method was eventually approved in 1998. Over two years, engineers removed around 70 tonnes of soil, gradually reducing the lean by half a meter without visible alteration to the monument. By June 2001, the tower had been successfully stabilized, restored to the inclination it had in the 18th century, and reopened to the public. The operation was hailed as one of the greatest feats of modern civil engineering, ensuring the survival of Pisa’s unique heritage for centuries to come. The documentary presents not only the technical challenges but also the cultural, historical, and emotional significance of preserving this medieval masterpiece. 13 October Battle of the Robots: The Hunt for AI, about the work of Hugo de Garis, Rodney Brooks, and Steve Grand (roboticist); the documentary opens with the archetypal and iconic robot HAL 9000 from the 1968 2001: A Space Odyssey (film) and The Blue Danube; Igor Aleksander, who worked in neural systems at Imperial College London, and his views on the likelihood of computational intelligence; Dan Dennett; British roboticist Steve Grand, of North Somerset made the world's first AI computer game Creatures in 1996, and was designing a glider that could teach itself; Blay Whitby of the University of Sussex; the MIT Computer Science and Artificial Intelligence Laboratory and Brian Scassellati, who was designing a social robot called Cog (project); Belgian Walter De Brouwer of Starlab in Belgium; engineer Kevin Warwick of the University of Reading at the 2001 Royal Society Prizes for Science Books (Aventis Prize for Science Books), won by Robert Kunzig. Narrated by Patrick Forbes, produced by Nicolas Kent 28 October Bioterror, an Equinox Special, about biological weapons, with Judith Miller and her 2001 book Germs: Biological Weapons and America's Secret War; Robert Kadlec of the National War College; science writer William Broad; the ATCC in Manassas, Virginia; microbiologist William C. Patrick III; the 2001 anthrax attacks; microbiologist Richard O. Spertzel; geneticist Matthew Meselson; Gennady Lepyoshkin, Director from 1987 to 2001 of a Russian secret biological research site; Jonathan B. Tucker; Chris Shays; Andrew C. Weber; Sergei Popov (bioweaponeer) had worked at the State Research Center for Applied Microbiology in Obolensk, Moscow Oblast. Produced by Matthew Collins, directed by Kirk Wolfinger, made by WGBH. Shown on Tuesday 20 November 2001 on The Nature of Things in Canada, and on Nova, and on Nova on Tuesday 13 November 2001
Sources: en.wikipedia.org
Cyclotides have been reported to have a wide range of biological activities, including anti-HIV, insecticidal, anti-tumour, antifouling, anti-microbial, hemolytic, neurotensin antagonism, trypsin inhibition, and uterotonic activities. An ability to induce uterine contractions was what prompted the initial discovery of kalata B1. The potent insecticidal activity of cyclotides kalata B1 and kalata B2 has prompted the belief that cyclotides act as plant host-defence agents. The observations that dozens or more cyclotides may be present in a single plant and the cyclotide architecture comprises a conserved core onto which a series of hypervariable loops is displayed suggest that cyclotides may be able to target many pests/pathogens simultaneously.
Formation of excessive scar tissue is thus prevented. The combination of silicone gel sheeting and compression therapy has been proven to be more effective than using the sheet alone. Patients who find the non-invasive treatments ineffective may choose to undergo invasive treatments such as intralesional injections of corticosteroids, surgical excision of the scars, and radiotherapy.
In 2000, crews organized by Jack Horner discovered five Tyrannosaurus skeletons near the Fort Peck Reservoir. In 2001, a 50% complete skeleton of a juvenile Tyrannosaurus was discovered in the Hell Creek Formation by a crew from the Burpee Museum of Natural History. Dubbed Jane (BMRP 2002.4.1), the find was thought to be the first known skeleton of a pygmy tyrannosaurid, Nanotyrannus, but other researchers considered it as the most complete juvenile T. rex; currently exhibited at the Burpee Museum of Natural History, Jane is now re-described as the holotype of N. lethaeus. In 2002, a skeleton nicknamed "Wyrex", discovered by amateur collectors Dan Wells and Don Wyrick, had 114 bones and was 38% complete. The dig was concluded in 2004 by the Black Hills Institute with the first live online Tyrannosaurus excavation. In 2006, Montana State University revealed that it possessed the largest Tyrannosaurus skull yet discovered (from a specimen named MOR 008), measuring 5 feet (152 cm) long. Subsequent comparisons indicated that the longest head was 136.5 centimetres (53.7 in) (from specimen LACM 23844) and the widest head was 90.2 centimetres (35.5 in) (from Sue).
== Detoxification and related reactions == 4-HNE has two reactive groups: the conjugated aldehyde and the C=C double-bond, and the hydroxy group at carbon 4. The α,β-unsaturated ketone serves as a Michael acceptor, adding thiols to give thioether adducts. A small group of enzymes are specifically suited to the detoxification and removal of 4-HNE from cells. Within this group are the glutathione S-transferases (GSTs) such as hGSTA4-4 and hGST5.8, aldose reductase, and aldehyde dehydrogenase. These enzymes have low Km values for HNE catalysis and together are very efficient at controlling the intracellular concentration, up to a critical threshold amount, at which these enzymes are overwhelmed and cell death is inevitable. Glutathione S-transferases hGSTA4-4 and hGST5.8 catalyze the conjugation of glutathione peptides to 4-hydroxynonenal through a conjugate addition to the alpha-beta unsaturated carbonyl, forming a more water-soluble molecule, GS-HNE. While there are other GSTs capable of this conjugation reaction (notably in the alpha class), these other isoforms are much less efficient and their production is not induced by the stress events which cause the formation of 4-HNE (such as exposure to hydrogen peroxide, ultraviolet light, heat shock, cancer drugs, etc.), as the production of the more specific two isoforms is. This result strongly suggests that hGSTA4-4 and hGST5.8 are specifically adapted by human cells for the purpose of detoxifying 4-HNE to abrogate the downstream effects which such a buildup would cause.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.